Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.

Related collections

Author and article information

Journal

PubMed ID:: 28467869

DOI:: 10.1056/NEJMoa1606910

Data availability:

Comments

Comment on this article

scite_

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Read this article at

Negative Pressure Wound Therapy

Journal

Comment on this article